REVIEW ARTICLES PSA mass screening: is there enough evidence?

Rocco, Bernardo; Grasso, Angelica; Sosnowski, Roman; Dell’Orto, P.; Albo, Giancarlo; Castle, Erik P.; Coelho, Rafael; Patel, Vip; Mottrie, Alexandre

doi:10.5173/ceju.2012.01.art1

Cited by 4 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This indicates that 75–88.2% of patients undergo unnecessary needle biopsies and are at risk of complications [ 5 ]. In addition, PSA levels are affected by factors such as the volume of the prostate, inflammation of the prostate, and BMI [ 6 , 7 , 8 , 9 ]. Therefore, prebiopsy prediction of PCa in patients with gray-zone PSA levels is a clinical challenge.…”

Section: Introductionmentioning

confidence: 99%

MRI-Based Radiomics Nomogram for Predicting Prostate Cancer with Gray-Zone Prostate-Specific Antigen Levels to Reduce Unnecessary Biopsies

Zhang

Tang

et al. 2022

Diagnostics

View full text Add to dashboard Cite

Objective: The aim of this study was to establish a predictive nomogram for predicting prostate cancer (PCa) in patients with gray-zone prostate-specific antigen (PSA) levels (4–10.0 ng/mL) based on radiomics and other traditional clinical parameters. Methods: In all, 274 patients with gray-zone PSA levels were included in this retrospective study. They were randomly divided into training and validation sets (n = 191 and 83, respectively). Data on the clinical risk factors related to PCa with gray-zone PSA levels (such as Prostate Imaging Reporting and Data System, version 2.1 [PI-RADS V2.1] category, age, prostate volume, and serum PSA level) were collected for all patients. Lesion volumes of interest (VOI) from T2-weighted imaging (T2WI) and apparent diffusion coefficient (ADC) imaging were annotated by two radiologists. The radiomics model, clinical model, and combined prediction model, which was presented on a nomogram by incorporating the radiomics signature and clinical and radiological risk factors for PCa, were developed using logistic regression. The area under the receiver operator characteristic (AUC-ROC) and decision, calibration curve were used to compare the three models for the diagnosis of PCa with gray-zone PSA levels. Results: The predictive nomogram (AUC: 0.953) incorporating the radiomics score and PI-RADS V2.1 category, age, and the radiomics model (AUC: 0.941) afforded much higher diagnostic efficacy than the clinical model (AUC: 0.866). The addition of the rad score could improve the discriminatory performance of the clinical model. The decision curve analysis indicated that the radiomics or combined model could be more beneficial compared to the clinical model for the prediction of PCa. The nomogram showed good agreement for detecting PCa with gray-zone PSA levels between prediction and histopathologic confirmation. Conclusion: The nomogram, which combined the radiomics score and PI-RADS V2.1 category and age, is an effective and non-invasive method for predicting PCa. Furthermore, as well as good calibration and is clinically useful, which could reduce unnecessary prostate biopsies in patients having PCa with gray-zone PSA levels.

show abstract

Section: Introductionmentioning

confidence: 99%

MRI-Based Radiomics Nomogram for Predicting Prostate Cancer with Gray-Zone Prostate-Specific Antigen Levels to Reduce Unnecessary Biopsies

Zhang

Tang

et al. 2022

Diagnostics

View full text Add to dashboard Cite

show abstract

“…Quant à sa prévalence, elle est de 59 % au-dessus de 80 ans (ce taux bien entendu n' est pas aussi important chez les patients plus jeunes, soit de 5 % en dessous de 30 ans) [1].…”

Section: Introductionunclassified

PSA et IRM: comment s’en servir de façon raisonnable pour la détection du cancer de la prostate

et al. 2020

View full text Add to dashboard Cite

RésuméLe cancer de la prostate est la deuxième tumeur la plus fréquemment diagnostiquée chez les hommes. Elle est responsable d’un impact significatif sur la mortalité ou la qualité de vie des patients, mais, contrairement à d’autres tumeurs, est parfois une maladie à lente progression.Une détection précoce avec dosage de lʼantigène prostatique spécifique (PSA) et un toucher rectal doit être proposé à tout sujet masculin bien informé sur ses conséquences.Le double but du dépistage est de diagnostiquer les cancers potentiellement mortels ou causant une morbidité importante, tout évitant la mise en place d’investigations et traitements agressifs pour des maladies de bas grade, surtout chez les patients âgés.Le PSA est un marqueur sensible mais non spécifique et son dosage doit être accompagné d’un contexte clinique précis, pour éviter la réalisation de biopsies superflues.Lʼimagerie par résonance magnétique multiparamétrique est un examen essentiel avant l’éventuelle réalisation d’une biopsie ainsi que pour la stadification et le suivi du cancer de la prostate (CaP).Des nouveaux biomarqueurs plus spécifiques sont attendus de longue date pour améliorer la détection précoce du CaP.

show abstract

Expression profile of human tissue kallikrein 15 provides preliminary insights into its roles in the prostate and testis

Filippou

Ren

Soosaipillai

et al. 2018

Clinical Biochemistry

View full text Add to dashboard Cite

REVIEW ARTICLES PSA mass screening: is there enough evidence?

Cited by 4 publications

References 15 publications

MRI-Based Radiomics Nomogram for Predicting Prostate Cancer with Gray-Zone Prostate-Specific Antigen Levels to Reduce Unnecessary Biopsies

MRI-Based Radiomics Nomogram for Predicting Prostate Cancer with Gray-Zone Prostate-Specific Antigen Levels to Reduce Unnecessary Biopsies

PSA et IRM: comment s’en servir de façon raisonnable pour la détection du cancer de la prostate

Expression profile of human tissue kallikrein 15 provides preliminary insights into its roles in the prostate and testis

Contact Info

Product

Resources

About